Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 56.73 per share at the end of the most recent trading day (a -0.86% change compared to the prior day closing price) with a volume of 11.56M shares and market capitalization of 118.51B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.

The one-year performance of Bristol-Myers Squibb Company stock is -19.65%, while year-to-date (YTD) performance is -21.15%. BMY stock has a five-year performance of -9.1%. Its 52-week range is between 57.12 and 81.435, which gives BMY stock a 52-week price range ratio of -1.60%

Bristol-Myers Squibb Company currently has a PE ratio of 23.80, a price-to-book (PB) ratio of 4.75, a price-to-sale (PS) ratio of 4.34, a price to cashflow ratio of 11.50, a PEG ratio of 4.67, a ROA of 6.95%, a ROC of 9.97% and a ROE of 20.80%. The company’s profit margin is 12.43%, its EBITDA margin is 41.30%, and its revenue ttm is $34.75 Billion , which makes it $16.35 revenue per share.

Of the last four earnings reports from Bristol-Myers Squibb Company, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.80 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 26th Oct 2023.

The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (2.29), with a target price of $80.08, which is +41.16% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bristol-Myers Squibb Company has a dividend yield of 3.21% with a dividend per share of $2.28 and a payout ratio of 273.00%.

Bristol-Myers Squibb Company has a Sell technical analysis rating based on Technical Indicators (ADX : 5.01, ATR14 : 0.89, CCI20 : -140.21, Chaikin Money Flow : -0.40, MACD : -0.92, Money Flow Index : 29.70, ROC : -3.07, RSI : 29.75, STOCH (14,3) : 2.92, STOCH RSI : 0.00, UO : 37.06, Williams %R : -97.08), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Lenkowsky (Option Excercise at a value of $0), Ann Powell Judge (Option Excercise at a value of $0), Ann Powell Judge (Sold 11 183 shares of value $835 258 ), Boerner Christopher (Option Excercise at a value of $0), Caforio Giovanni (Option Excercise at a value of $0), Caforio Giovanni (Sold 240 000 shares of value $17 916 000 ), Christopher S. Boerner (Option Excercise at a value of $0), David V. Elkins (Option Excercise at a value of $0), Elizabeth A. Mily (Option Excercise at a value of $0), Elizabeth Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 240 000 shares of value $17 916 000 ), Gregory Scott Meyers (Sold 0 shares of value $0 ), Karin Shanahan (Sold 0 shares of value $0 ), Leung Sandra (Option Excercise at a value of $0), Michelle Weese (Option Excercise at a value of $0), Powell Ann Judge (Option Excercise at a value of $0), Powell Ann Judge (Sold 27 433 shares of value $2 142 570 ), Rupert Vessey (Option Excercise at a value of $4 643 869), Rupert Vessey (Sold 142 205 shares of value $10 621 578 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sharon Greenlees (Sold 0 shares of value $0 )